Eli Lilly Option Alert: Jan, 2027 $900 Calls at the Bid: 50 vs 439 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Jan, 2027 $900 Calls at the Bid: 50 @ $115.1 vs 439 OI; Earnings 10/30 Before Open Ref=$840.89

Eli Lilly Option Alert: Jun 18 $840 Calls Sweep (15) near the Bid: 70 vs 78 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Jun 18 $840 Calls Sweep (15) near the Bid: 70 @ $94.0 vs 78 OI; Earnings 10/30 Before Open Ref=$820.15

Eli Lilly Option Alert: Nov 21 $830 Calls at the Ask: 160 vs 399 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Nov 21 $830 Calls at the Ask: 160 @ $42.95 vs 399 OI; Earnings 10/30 Before Open Ref=$820.12

Eli Lilly Option Alert: Jun 18 $1000 Calls Sweep (18) above Ask!: 125 vs 1785 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Jun 18 $1000 Calls Sweep (18) above Ask!: 125 @ $43.0 vs 1785 OI; Earnings 10/30 Before Open Ref=$819.2

Eli Lilly Option Alert: Jun 18 $940 Calls at the Bid: 700 vs 31 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Jun 18 $940 Calls at the Bid: 700 @ $57.0 vs 31 OI; Earnings 10/30 Before Open Ref=$818.92

Eli Lilly Option Alert: Jun, 2027 $650 Calls at the Ask: 40 vs 283 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Jun, 2027 $650 Calls at the Ask: 40 @ $246.0 vs 283 OI; Earnings 10/30 Before Open Ref=$812.2

Eli Lilly Option Alert: Jun, 2027 $650 Calls Sweep (5) near the Ask: 30 vs 283 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Jun, 2027 $650 Calls Sweep (5) near the Ask: 30 @ $245.11 vs 283 OI; Earnings 10/30 Before Open Ref=$812.23

Eli Lilly Option Alert: Jun 18 $800 Calls Sweep (21) near the midpoint: 51 vs 943 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Jun 18 $800 Calls Sweep (21) near the midpoint: 51 @ $105.966 vs 943 OI; Earnings 10/30 Before Open Ref=$809.31

Eli Lilly Option Alert: Jan, 2027 $720 Calls at the Ask: 50 vs 209 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Jan, 2027 $720 Calls at the Ask: 50 @ $174.15 vs 209 OI; Earnings 10/30 Before Open Ref=$797.615

Eli Lilly Option Alert: Jun 18 $1000 Calls Sweep (6) near the Ask: 255 vs 1125 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Jun 18 $1000 Calls Sweep (6) near the Ask: 255 @ $25.0 vs 1125 OI; Earnings 10/30 Before Open Ref=$754.26

Eli Lilly Option Alert: Nov 21 $710 Calls Sweep (4) near the Ask: 100 vs 181 OI; Earnings 10/30 Before Open 

Eli Lilly Option Alert: Nov 21 $710 Calls Sweep (4) near the Ask: 100 @ $60.038 vs 181 OI; Earnings 10/30 Before Open Ref=$736.74

Eli Lilly Option Alert: Dec, 2026 $980 Calls at the Bid: 135 vs 254 OI; Earnings 10/29 Before Open [est] 

Eli Lilly Option Alert: Dec, 2026 $980 Calls at the Bid: 135 @ $40.1 vs 254 OI; Earnings 10/29 Before Open [est] Ref=$725.38

Eli Lilly Option Alert: Jan, 2027 $760 Puts Sweep (6) near the Ask: 49 vs 137 OI; Earnings 10/29 Before Open [est] 

Eli Lilly Option Alert: Jan, 2027 $760 Puts Sweep (6) near the Ask: 49 @ $116.366 vs 137 OI; Earnings 10/29 Before Open [est] Ref=$720.715

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Logo,Pfizer,Inc.,Is,An,American,Multinational,Pharmacological,And,Biotechnology

Long Ideas

Health Care

Trading Ideas

General

L&#39;intesa definisce nuovi equilibri nel settore sanitario americano, sollevando interrogativi sui profitti di giganti assicurativi e farmaceutici concorrenti.

Accordo Pfizer-Washington: vantaggio a sorpresa o campanello d&#39;allarme?

Prague,,Czechia,-,30.,May,2025:,Eli,Lilly,Logo,Sign

Biotech

Large Cap

News

Movers

L&#39;agenzia regolatoria statunitense dà il via libera a una nuova terapia mirata per una forma aggressiva di carcinoma mammario.

Cancro al seno: la FDA approva il nuovo farmaco di Eli Lilly

Krasnoyarsk,,Russia,-,April,29,,2021:,Pfizer,Vaccine,Vial,With

Invesco Managed Futures Strategy ETF Invesco International Growth Focus ETF

MTRA

MTSR

La società farmaceutica si prepara a una mossa che potrebbe rilanciare i suoi orizzonti nel settore dei farmaci per perdere peso.

Pfizer punta su un farmaco dimagrante per competere con Eli Lilly e Novo Nordisk

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

Liberty Media Corporation - Series C Liberty Live Common Stock

Liberty Live Group

Liberty Media Corporation - Series A Liberty Live Common Stock

Defiance Daily Target 2X Short LLY ETF

LIBERTY LIVE SERIES B by Liberty Media Corporation

Press Releases

Lilly launches new "Brain Health Matters" campaign in partnership with Julianne Moore, empowering the public to prioritize brain health

Lilly to participate in Bernstein's 2nd Annual Healthcare Forum

Lilly announces plans to build $5 billion manufacturing facility in Virginia

Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine

Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes

Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas

U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease

Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Merck & Co

Novo Nordisk

Novartis

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Morgan Stanley

Berenberg

JP Morgan

HSBC

Cantor Fitzgerald

Screenshot 2025-07-08 at 5.24.00 PM

ADBE

SBC Medical Group In Growth Mode: Company Gets Added To The Russell 3000 Index, Names New Chief Marketing Officer

Untitled design - 2025-03-31T165341.547

TNXP

VRTX

Tonix&#39;s Experimental Non-Opioid Analgesic Treatment For Fibromyalgia Could Start Bringing Relief Later This Year

Screenshot 2025-02-24 at 11.35.34 PM

BRTX

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

Screenshot 2024-11-20 at 6.30.30 PM

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
11:09 AMOct 03, 2025	CALL	$900.00	Jan 15, 2027	466	324	50	74	439	TRADE	BEARISH
12:49 PMOct 02, 2025	CALL	$840.00	Jun 18, 2026	255	70	70	90	78	SWEEP	BEARISH
10:00 AMOct 02, 2025	CALL	$830.00	Nov 21, 2025	46	173	160	43	399	TRADE	BULLISH
01:03 PMOct 01, 2025	CALL	$1000.00	Jun 18, 2026	255	588	125	33	1785	SWEEP	BULLISH
12:52 PMOct 01, 2025	CALL	$940.00	Jun 18, 2026	255	2043	700	6590	31	TRADE	BEARISH
11:37 AMOct 01, 2025	CALL	$650.00	Jun 17, 2027	619	78	40	28	283	TRADE	BULLISH
11:36 AMOct 01, 2025	CALL	$650.00	Jun 17, 2027	619	38	30	13	283	SWEEP	BULLISH
11:05 AMOct 01, 2025	CALL	$800.00	Jun 18, 2026	255	94	51	10	943	SWEEP	NEUTRAL
10:35 AMOct 01, 2025	CALL	$720.00	Jan 15, 2027	466	50	50	24	209	TRADE	BULLISH
01:24 PMSep 30, 2025	CALL	$1000.00	Jun 18, 2026	255	262	255	23	1125	SWEEP	BULLISH
12:28 PMSep 30, 2025	CALL	$710.00	Nov 21, 2025	46	100	100	55	181	SWEEP	BULLISH
02:41 PMSep 29, 2025	CALL	$980.00	Dec 18, 2026	438	138	135	54	254	TRADE	BEARISH
11:50 AMSep 26, 2025	PUT	$760.00	Jan 15, 2027	466	54	49	39	137	SWEEP	BEARISH

Comments

Eli Lilly

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO